Yesterday Biogen announced the purchase of a single phase-2 ready neuro drug from Pfizer for $75 million upfront, plus milestones of up to $515 million and royalties.
The drug was being developed by Pzifer for the treatment of cognitive symptoms in schizophrenia, and has completed phase 1 safety trials.
The value of this deal is similar to Bell Potter’s estimate for trofinetide, however I think it is closer to what Neuren could get for NNZ-2591.
https://www.fiercebiotech.com/biote...unwanted-neuro-med-for-75m-as-sell-off-starts
Yesterday Biogen announced the purchase of a single phase-2...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.070(0.35%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| $20.22 | $20.44 | $19.85 | $4.194M | 209.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2772 | $19.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 3310 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |